CA
LKFT

Continental Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Continental Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$526K – 63
2021
Q3 		$526K Buy
+10,000
New +$594K 0.22% 62

Other funds holding LKFT

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Continental Advisors's LKFT Position: Q4 2021 in Review

Continental Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2021, closing a stake of 10,000 shares — an estimated $526K sold.

Continental Advisors first reported a position in LKFT in Q3 2021 and held it in 1 quarter. The position peaked at $526K in Q3 2021. 83 funds tracked by Wall St. Rank hold LKFT as of Q4 2021.

  • Continental Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2021 after selling out during the quarter.
  • Continental Advisors sold 10,000 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2021, an estimated $526K.
  • Continental Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2021 and held it in 1 quarter.
  • Continental Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $526K in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2021.

Based on Continental Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.